Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MEAGEN REBECCA SALINAS

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1508209875
CMS profile
4223908
Location
ENGLEWOOD, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$21,714.39

102 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MEAGEN REBECCA SALINAS

NPI 1508209875 · CMS profile ID 4223908

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

ENGLEWOOD, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508209875?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MEAGEN REBECCA SALINAS, NPI 1508209875, CMS profile ID 4223908. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508209875?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MEAGEN REBECCA SALINAS, NPI 1508209875, CMS profile ID 4223908. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508209875?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MEAGEN REBECCA SALINAS, NPI 1508209875, CMS profile ID 4223908, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1508209875?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

102 matching records · $21,714.39 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 102 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 102.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boston Scientific Corporation $184.8406/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181310762 CMS
ABBVIE INC. $28.3206/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204022769 CMS
Neurocrine BioSciences, Inc. $21.7106/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243018967 CMS
ACADIA Pharmaceuticals Inc $24.8506/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247797235 CMS
MDD US Operations, LLC $14.7706/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241858945 CMS
Teva Pharmaceuticals USA, Inc. $34.8905/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247331812 CMS
Merz Pharmaceuticals, LLC $15.0905/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232564367 CMS
ACADIA Pharmaceuticals Inc $16.5105/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247797231 CMS
Abbott Laboratories $134.0005/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240721604 CMS
H. Lundbeck A S $3,363.7505/14/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1251762502 CMS
H. Lundbeck A S $649.3205/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1251762505 CMS
Boston Scientific Corporation $201.3505/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181310754 CMS
Boston Scientific Corporation $113.2805/03/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1181310758 CMS
Boston Scientific Corporation $382.6905/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1181310756 CMS
Biogen, Inc. $14.9104/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208378853 CMS
Neurocrine BioSciences, Inc. $34.4804/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242979245 CMS
Teva Pharmaceuticals USA, Inc. $2,573.0004/23/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1247331826 CMS
Teva Pharmaceuticals USA, Inc. $8.1204/17/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1247331784 CMS
Teva Pharmaceuticals USA, Inc. $123.9804/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247331786 CMS
Teva Pharmaceuticals USA, Inc. $4,165.0004/17/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1247331788 CMS
Teva Pharmaceuticals USA, Inc. $28.7804/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247331900 CMS
Medtronic, Inc. $17.9304/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218914023 CMS
ABBVIE INC. $13.7804/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204022763 CMS
Merz Pharmaceuticals, LLC $22.7004/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232564369 CMS
Teva Pharmaceuticals USA, Inc. $6.9404/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247331772 CMS
Neurocrine BioSciences, Inc. $166.9604/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242961769 CMS
ABBVIE INC. $7.3404/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204022757 CMS
REVANCE THERAPEUTICS, INC. $51.1004/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251172477 CMS
ABBVIE INC. $30.1703/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204022751 CMS
Teva Pharmaceuticals USA, Inc. $30.0903/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247331898 CMS
Teva Pharmaceuticals USA, Inc. $4,165.0003/13/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1247331748 CMS
Teva Pharmaceuticals USA, Inc. $17.3303/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247331758 CMS
Teva Pharmaceuticals USA, Inc. $80.7603/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247331756 CMS
ABBVIE INC. $27.1103/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204022746 CMS
Abbott Laboratories $19.2903/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240720212 CMS
Neurocrine BioSciences, Inc. $18.5003/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243031946 CMS
ACADIA Pharmaceuticals Inc $24.0802/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247797227 CMS
Merz Pharmaceuticals, LLC $18.5002/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232564365 CMS
MDD US Operations, LLC $22.2402/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241858939 CMS
ABBVIE INC. $144.8302/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204022741 CMS
ABBVIE INC. $32.2702/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204022735 CMS
MDD US Operations, LLC $24.2602/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241858941 CMS
ACADIA Pharmaceuticals Inc $23.0801/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247797223 CMS
ABBVIE INC. $29.7901/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204022727 CMS
Cala Health, Inc. $18.7801/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244111972 CMS
Cala Health, Inc. $18.7801/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244270391 CMS
MDD US Operations, LLC $24.6301/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241858937 CMS
ACADIA Pharmaceuticals Inc $22.0001/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247797219 CMS
ABBVIE INC. $23.7201/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204022723 CMS
ACADIA Pharmaceuticals Inc $8.3501/13/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1247797216 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $663.57 7
PY2022 $82.09 1
PY2023 $74.47 2
PY2024 $1,335.21 40
PY2025 $21,714.39 102

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,319,832.39 56

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

56 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,656.72 12/31/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL
An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of ABBV-951 in Subjects With Advanced Parkinson s Disease No dispute reported 06/30/2026 1202534771
Principal investigator 1 ABBVIE INC. $780.30 12/24/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202532048
Principal investigator 1 UCB SA $27.89 12/05/2025 Non-covered Recipient Entity
SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE, NEUROSCIENCES INSTITUTE - DEPT OF NEUROLOGY
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, OUTPATIENT, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF STACCATO ALPRAZOLAM IN STUDY PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH STEREOTYPICAL PROLONGED SEIZURES No dispute reported 06/30/2026 1246658090
Principal investigator 1 H. Lundbeck A S $2,353.00 12/04/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251777977
Principal investigator 1 H. Lundbeck A S $3,534.00 12/04/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251777981
Principal investigator 1 H. Lundbeck A S $16,193.00 12/04/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251777985
Principal investigator 1 H. Lundbeck A S $7,172.00 12/04/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251777990
Principal investigator 1 H. Lundbeck A S $4,454.00 12/04/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251777993
Principal investigator 1 H. Lundbeck A S $2,466.00 12/04/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251777997
Principal investigator 1 H. Lundbeck A S $4,706.00 12/04/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251778001
Principal investigator 1 H. Lundbeck A S $5,887.00 12/04/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251778005
Principal investigator 1 H. Lundbeck A S $15,030.00 12/04/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251778009
Principal investigator 1 H. Lundbeck A S $6,450.00 12/04/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251778013
Principal investigator 1 H. Lundbeck A S $2,450.00 12/04/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251778018
Principal investigator 1 ABBVIE INC. $1,045.45 11/26/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202525440
Principal investigator 1 Roche TCRC, Inc. $16,501.50 11/13/2025 Non-covered Recipient Entity
ROCKY MOUNTAIN MOVEMENT DISORDERS CTR
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211648224
Principal investigator 1 Roche TCRC, Inc. $81.00 11/13/2025 Non-covered Recipient Entity
ROCKY MOUNTAIN MOVEMENT DISORDERS CTR
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211648228
Principal investigator 1 Genentech, Inc. $82,240.00 11/03/2025 Non-covered Recipient Entity
ROCKY MOUNTAIN MOVEMENT DISORDERS CENTER PC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211648198
Principal investigator 1 H. Lundbeck A S $4,876.00 10/29/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251776377
Principal investigator 1 ABBVIE INC. $741.76 10/09/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202516469
Principal investigator 1 ABBVIE INC. $500.00 09/23/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202511922
Principal investigator 1 ABBVIE INC. $3,807.82 09/11/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202510802
Principal investigator 1 Roche TCRC, Inc. $6,043.50 09/11/2025 Non-covered Recipient Entity
ROCKY MOUNTAIN MOVEMENT DISORDERS CTR
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211648217
Principal investigator 1 H. Lundbeck A S $15,282.00 08/26/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251773932
Principal investigator 1 ABBVIE INC. $3,280.50 08/14/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202504667
Principal investigator 1 H. Lundbeck A S $15,395.00 08/14/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251773605
Principal investigator 1 Roche TCRC, Inc. $11,977.20 08/14/2025 Non-covered Recipient Entity
ROCKY MOUNTAIN MOVEMENT DISORDERS CTR
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211648221
Principal investigator 1 Roche TCRC, Inc. $250.00 08/13/2025 Non-covered Recipient Entity
ROCKY MOUNTAIN MOVEMENT DISORDERS CTR
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211648213
Principal investigator 1 H. Lundbeck A S $90,034.00 07/31/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251772886
Principal investigator 1 H. Lundbeck A S $36.04 07/31/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251772968
Principal investigator 1 UCB SA $5,081.00 07/30/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN
A dose-blinded extension study to evaluate the long-term efficacy, safety, and tolerability of UCB0599 in study participants with Parkinsons disease No dispute reported 06/30/2026 1246658714
Principal investigator 1 Genentech, Inc. $6,788.00 07/23/2025 Non-covered Recipient Entity
ROCKY MOUNTAIN MOVEMENT DISORDERS CENTER PC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211648188
Principal investigator 1 H. Lundbeck A S $1,000.00 07/17/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251772484
Principal investigator 1 H. Lundbeck A S $298.92 07/17/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251772488
Principal investigator 1 H. Lundbeck A S $300.00 07/17/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251772492
Principal investigator 1 ABBVIE INC. $673.65 07/10/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202497924
Principal investigator 1 H. Lundbeck A S $8,466.00 07/10/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251772025
Principal investigator 1 H. Lundbeck A S $2,353.00 07/04/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251771737
Principal investigator 1 ABBVIE INC. $3,175.20 07/02/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202495169
Principal investigator 1 ABBVIE INC. $250.00 07/01/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202493797
Principal investigator 1 H. Lundbeck A S $44,385.00 06/24/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251771507
Principal investigator 1 Roche TCRC, Inc. $22,995.90 06/13/2025 Non-covered Recipient Entity
ROCKY MOUNTAIN MOVEMENT DISORDERS CTR
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211648210
Principal investigator 1 H. Lundbeck A S $9,751.00 06/05/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251770733
Principal investigator 1 Genentech, Inc. $79,822.00 05/16/2025 Non-covered Recipient Entity
ROCKY MOUNTAIN MOVEMENT DISORDERS CENTER PC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211648178
Principal investigator 1 H. Lundbeck A S $13,042.00 05/15/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251770315
Principal investigator 1 H. Lundbeck A S $5,538.00 05/15/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251770330
Principal investigator 1 H. Lundbeck A S $175.50 05/15/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251770334
Principal investigator 1 H. Lundbeck A S $8,466.00 05/08/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251770119
Principal investigator 1 H. Lundbeck A S $10,576.00 04/01/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251769253
Principal investigator 1 H. Lundbeck A S $10,576.00 03/25/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251769032
Principal investigator 1 H. Lundbeck A S $2,466.00 03/19/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251768861
Principal investigator 1 H. Lundbeck A S $8,000.00 03/04/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251768033
Principal investigator 1 H. Lundbeck A S $2,000.00 03/04/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251768037
Principal investigator 1 H. Lundbeck A S $12,000.00 03/04/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251768041
Principal investigator 1 H. Lundbeck A S $10,576.00 02/18/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251767413
Principal investigator 1 Eli Lilly and Company $725,825.54 02/03/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN RESEARC
A PHASE 1/2A OPEN-LABEL ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND EFFECTS OF LY3884961 IN PATIENTS WITH PARKINSON'S DISEASE WITH AT LEAST ONE GBA1 MUTATION (PROPEL) No dispute reported 06/30/2026 1187877395